ATAI Life Sciences N.V.
Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
IPO Year: 2008
Exchange: NASDAQ
Website: atai.life
Recent Analyst Ratings for ATAI Life Sciences N.V.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/18/2024 | $15.00 → $10.00 | Buy | H.C. Wainwright |
4/3/2024 | $6.00 | Hold → Buy | Maxim Group |
11/1/2022 | $18.00 | Buy | Loop Capital |
11/30/2021 | $25.00 | Buy | Maxim Group |
11/22/2021 | $40.00 → $50.00 | Buy | HC Wainwright & Co. |
11/16/2021 | $25.00 → $24.00 | Outperform | Credit Suisse |
11/16/2021 | $19.00 → $17.00 | Sector Perform | RBC Capital |
11/11/2021 | $32.00 | Buy | Roth Capital |
10/18/2021 | $40.00 | Buy | HC Wainwright & Co. |
9/1/2021 | $27.00 | Buy | Jefferies |
ATAI Life Sciences N.V. Press Releases
Fastest customizable press release news feed in the world
atai Life Sciences Announces Pricing of Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering will be sold by atai. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by atai, are expected to be approximately $55 mi
atai Life Sciences Announces Proposed Public Offering of Common Shares
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering will be sold by atai. atai intends to use the net proceeds from this offering for general corporate purposes, including for working capital and to advance the clinical development of its product candi
atai Life Sciences Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months - BPL-003 was well-tolerated with no serious or severe adverse events reported NEW YORK and BERLIN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced positive topline results from Beckley Psytech's Phase 2a open-label study of BPL-003 in 12 patients with moderate to severe alcohol use disorder (AUD). BPL-003 is a patent-protected
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 - Remain on track to initiate a Phase 2 study of EMP-01 (oral R-MDMA) in social anxiety disorder patients around YE'24 - Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorder
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), effective immediately. Mr. Weaver will lead the Company's finance and accounting functions, including SEC reporting and investor relations. "We are pleased to welcome Greg to Altimmune's executive team during such a pivotal time in our evolution. He has a wealth of experience that we believe will be invaluable as we enter a crucial period in the development of our lead program, pemvidutide and in our advancement as an organization," said Vipin K. Garg, Ph.D., President and Chief Execu
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company's Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from October 15 – 17, 2024. Details of the company's participation: Format: Virtual fireside chat Date: Wednesday, October 16, 2024 Presentation Time: 3:30 P.M. EDTWebcast: Register here An archived replay will be available on the Investors section of the atai website under Events for up to 30 days. About at
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Tuesday, September 10 at 4:30 P.M. EDTWebcast link: Here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days. Ab
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE'24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced second quarter 2024 financial results and pr
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatryVLS-01 reached peak plasma concentration within 30-45 minutes and was shown to induce a short psychedelic experience, with subjective effects generally resolving within 90-120 minutesVLS-01 demonstrated a favorable safety profile and was well tolerated, with all adverse events classified as either mild or moderate, and most resolving on the day of dosingatai expects to initiate a randomized, double-blind, placebo-controlled Phase 2 study of VLS-01 to assess the efficacy, safety and durability of respon
ATAI Life Sciences N.V. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright reiterated coverage on atai Life Sciences N.V. with a new price target
H.C. Wainwright reiterated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $10.00 from $15.00 previously
atai Life Sciences N.V. upgraded by Maxim Group with a new price target
Maxim Group upgraded atai Life Sciences N.V. from Hold to Buy and set a new price target of $6.00
Loop Capital initiated coverage on atai Life Sciences N.V. with a new price target
Loop Capital initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $18.00
Maxim Group initiated coverage on atai Life Sciences N.V. with a new price target
Maxim Group initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $25.00
HC Wainwright & Co. reiterated coverage on ATAI Life Sciences with a new price target
HC Wainwright & Co. reiterated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $50.00 from $40.00 previously
Credit Suisse reiterated coverage on ATAI Life Sciences with a new price target
Credit Suisse reiterated coverage of ATAI Life Sciences with a rating of Outperform and set a new price target of $24.00 from $25.00 previously
RBC Capital reiterated coverage on ATAI Life Sciences with a new price target
RBC Capital reiterated coverage of ATAI Life Sciences with a rating of Sector Perform and set a new price target of $17.00 from $19.00 previously
Roth Capital initiated coverage on ATAI Life Sciences with a new price target
Roth Capital initiated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $32.00
HC Wainwright & Co. initiated coverage on ATAI Life Sciences with a new price target
HC Wainwright & Co. initiated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $40.00
Jefferies initiated coverage on atai Life Sciences N.V. with a new price target
Jefferies initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $27.00
ATAI Life Sciences N.V. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Brand Florian bought $23,120 worth of shares (20,000 units at $1.16), increasing direct ownership by 18% to 130,000 units (SEC Form 4)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
ATAI Life Sciences N.V. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 4 filed by Officer Rao Srinivas
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
SEC Form 3 filed by new insider Craig Kevin James
3 - ATAI Life Sciences N.V. (0001840904) (Issuer)
New insider Short Glenn Frank claimed ownership of 22,994 shares (SEC Form 3)
3 - ATAI Life Sciences N.V. (0001840904) (Issuer)
SEC Form 4 filed by Chief Operating Officer Kochendoerfer Gerd
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
SEC Form 3 filed by new insider Kochendoerfer Gerd
3 - ATAI Life Sciences N.V. (0001840904) (Issuer)
SEC Form 4 filed by Director Angermayer Christian
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
SEC Form 4 filed by Chief Financial Officer Johnson Anne Nagengast
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
SEC Form 4 filed by Officer Brand Florian
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
SEC Form 4 filed by Officer Rao Srinivas
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
Large owner Atai Life Sciences N.V. sold $16,093,000 worth of Ordinary Shares (2,660,000 units at $6.05) (SEC Form 4)
4 - ATAI Life Sciences N.V. (0001840904) (Reporting)
ATAI Life Sciences N.V. SEC Filings
ATAI Life Sciences N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
SEC Form 424B5 filed by ATAI Life Sciences N.V.
424B5 - ATAI Life Sciences N.V. (0001840904) (Filer)
SEC Form 424B5 filed by ATAI Life Sciences N.V.
424B5 - ATAI Life Sciences N.V. (0001840904) (Filer)
ATAI Life Sciences N.V. filed SEC Form 8-K: Leadership Update
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
ATAI Life Sciences N.V. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
Amendment: SEC Form 10-Q/A filed by ATAI Life Sciences N.V.
10-Q/A - ATAI Life Sciences N.V. (0001840904) (Filer)
SEC Form 10-Q filed by ATAI Life Sciences N.V.
10-Q - ATAI Life Sciences N.V. (0001840904) (Filer)
ATAI Life Sciences N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
ATAI Life Sciences N.V. filed SEC Form 8-K: Other Events
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
ATAI Life Sciences N.V. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
ATAI Life Sciences N.V. Leadership Updates
Live Leadership Updates
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer NEW YORK and BERLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao M.D., Ph.D., has assumed the role of sole Chief Executive Officer (CEO), joined by the promotions of Kevin Craig, M.D.
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp
Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer
SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee - - He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries - - His deal sheet includes transactions totaling more than USD 2.7 billion in CNS and beyond - NEW YORK and BERLIN, Nov. 29, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (NASDAQ:ATAI) ("atai" or the "Company"), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today its appointment of Dr. Kirpekar to serve as the Company's Chief Busines
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mushrooms can be used to treat depression. Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. According to CAMH's lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce "sustained antidepressant effects" in individuals living with severe depression. This news comes just days after a major scientific review found "no clear evidence
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Kures Therapeutics, Inc ("Kures"), an atai Life Sciences N.V. (NASDAQ:ATAI) ("atai") company focused on developing treatment options to better manage addictions, depression, and pain, today announced the appointment of Chad E. Beyer, Ph.D., MBA, currently Senior Vice President of Research and Development at Promentis Pharmaceuticals, Inc ("Promentis"), as Chief Executive Officer of Kures, effective July 1, 2022. Dr. Beyer has over 25 years of experience in the discovery, research and translational development of medications that treat the central nervous system and neurological disorders. He has led several preclinical and clinical drug discove
ATAI Life Sciences N.V. Financials
Live finance-specific insights
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai's existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24 BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects Anticipated synergies th
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics ketamine trials – Eight new programs added to platform since January 2021 bringing total, as of today, to 13 discovery and drug development programs and four enabling technologies – Ended 2021 very well capitalized with $362 million to execute our strategy to achieve clinically meaningful and sustai
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update. To access the webcast, please log in at https://wsw.com/webcast/cc/atai/1358298. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life. About atai Life Sciences atai was founded in 2018 as a response to the significant
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
-Positive topline results from COMP360's Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11 therapeutic programs, including initiation of Perception's Phase 2a and DemeRx's Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort- -Launch of atai Impact, a philanthropic program to harness the power of innovative mental health approaches for social change- -Company to host a webcast and conference call today at 08:30am EST- BERLIN and NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company ai
atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update. To access the live conference call, please dial 877-407-3982 from the United States, or +1 (201) 493-6780 internationally, using the conference ID: 13724750. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life.
atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update. To access the live conference call, please dial 877-407-3982 from the United States, or +1 (201) 493-6780 internationally, using the conference ID: 13721888. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life. Abou
ATAI Life Sciences N.V. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13D/A filed by ATAI Life Sciences N.V.
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SEC Form SC 13G/A filed by ATAI Life Sciences N.V. (Amendment)
SC 13G/A - ATAI Life Sciences N.V. (0001840904) (Subject)
SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SEC Form SC 13G/A filed by ATAI Life Sciences N.V. (Amendment)
SC 13G/A - ATAI Life Sciences N.V. (0001840904) (Subject)
SEC Form SC 13G filed by ATAI Life Sciences N.V.
SC 13G - ATAI Life Sciences N.V. (0001840904) (Subject)
SEC Form SC 13G filed by ATAI Life Sciences N.V.
SC 13G - ATAI Life Sciences N.V. (0001840904) (Subject)
SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SEC Form SC 13D/A filed by ATAI Life Sciences N.V. (Amendment)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)